Kornimate/medical-research-clean huggingface dataset:
effectiveness of mat pilates exercises in individuals with chronic nonspecific low back pain

Conditions: Nonspecific Chronic Low Back Pain; Chronic Low Back Pain

Summary: to analyze the effectiveness of mat pilates compared to no intervention in individuals with chronic nonspecific low back pain.

there is evidence that exercises based on the pilates method reduce pain in chronic nonspecific low back pain (cnlbp). however, is noticed the lack of studies that compare the effectiveness of mat pilates to no intervention in the treatment of individual with cnlbp. therefore, the main objective of the study is to analyze the effectiveness of mat pilates compared to no intervention in patients with chronic nonspecific low back pain. it is a randomized controlled trial with two arms and double blinded (caregiver, assessor and outcome assessor), composed of 30 patients, aged between 18- 65 years (±22,47) of both sexes, diagnosed with chronic non-specific low back pain persisting for more than three months and pain intensity greater than 3 points in the pain numerical rating scale. the participants were randomly divided into two groups: pilates group (n = 15), intervention based on mat pilates exercises, and control group (n =15) with no intervention. the mat pilates group performed 16 sessions, twice a week in 60-minute duration each throughout eight weeks, whereas the control group participants kept usual cares until the end of the intervention. both groups were evaluated before and after the program by a researcher who was unaware of the patients' allocation. the primary assessed outcomes: pain intensity (pain numerical rating scale, and mcgill questionnaire), quality of life (sf-36), and disability (oswestry low back pain disability questionnaire). in addition, the strength and muscle activation of transverse abdominal as secondary outcome assessed through the stabilizer pressure biofeedback unit test. as a result, the study infers that mat pilates exercises have significantly improved all the evaluated outcomes. thus, supporting clinical decisions for the treatment of chronic nonspecific low back pain.

Eligibility criteria:
inclusion criteria: * complaining of non-specific low back pain for more than three months without radicular symptoms for a period exceeding 12 months. * pain intensity equal to or more than 3 points evaluated by the pain numerical rating scale in the last seven days. * eligibility to practice physical activity responding to the physical activity readiness questionnaire - par-q exclusion criteria: * degenerative or inflammatory pathologies of the spine, * acute crisis of pain in the shoulders, knees, ankles and spine * spinal tumors * recent surgery on the spine, lower and upper limbs * herniated disc * spondylolysis or spondylolisthesis * rheumatologic diseases * patients who are in labor dispute * in treatment involving pilates, physiotherapy or medication. * do not understand the writing and speaking portuguese.

Keywords: mat pilates chronic nonspecific low back pain quality of life disability transverse abdominal muscle
a single time-point study to evaluate the conformis itotal® (cr) knee versus off-the-shelf

Conditions: Osteoarthritis

Summary: it has been noted that patients "dramatically overestimate their functional ability early after surgery." despite use of assistive devices increasing and functional testing scores decreasing post-surgery, the patient reported outcome scores fail to show worsening. outcome questionnaires will be administered and functional testing will be conducted on all patients to capture these changes.

the functional testing used in this study consists of tests that physical therapists use daily as objective methods to assess patients' functional status. the testing is designed to closely mimic daily activities that the patients are familiar with.

Eligibility criteria:
inclusion criteria: * implant must be at least 6 months post-op and doing well * patient has had a total cr knee implant * \> 18 years of age exclusion criteria: * simultaneous bilateral procedure occurred * bmi \> 40 * other physical disability that requires an aid for walking or disability affecting the hips, spine, contralateral knee or other joint that limits function * participation in another clinical study which would confound results * inability to complete the protocol in the opinion of the clinical staff due to safety or other reasons
better first aid with first aid training and dispatcher central instructions?

Conditions: Injury

Summary: the study evaluates the effect of a first aid course on first aid skills compared to no training. the study also evaluates the effect of first-aid instructions given by emergency dispatch central over mobile phone on first aid performance to no instructions. half the participants will perform first aid in two scenarios prior to first aid training. half the participants will perform first aid in two scenarios 4 to 5 months after attending a first aid course. half the participants (overall) will receive first aid instructions by mobile phone during the scenarios.


Eligibility criteria:
inclusion criteria: * students in high school/college exclusion criteria: -

Keywords: out of hospital cardiac arrest first aid
establishment of a clinical and prognostic follow-up cohort of migraine patients with patent foramen ovale

Conditions: Migraine; Patent Foramen Ovale

Summary: to establish a headache center in china that combines clinical, imaging and laboratory examinations, explore the feasible treatment options for migraine combined with patent foramen ovale, and search for the possible influencing factors, construct models that influence prognosis.


Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for migraine in the international classification of headache (ichd-3); * confirmation of patent foramen ovale through transthoracic echocardiography(tte) or transesophageal echocardiography(tee)/right heart contrast echocardiography * agree to participate in the study and sign the informed consent form. exclusion criteria: * can not sign the informed consent form or cooperate with follow-up.
hydrocortisone replacement in patients with secondary adrenal insufficiency (supreme cort)

Conditions: Adrenal Insufficiency

Summary: the aim of this study is to investigate whether a physiologically low hydrocortisone (hc) dose is better for cognition as compared to a physiologically high hc dose. in addition, quality of life, metabolic profile and somatosensation will be described in relation to hc dose.

* rationale: a wide variety in hydrocortisone (hc) substitution dose-regimens are considered physiological for patients with adrenal insufficiency. however, it is likely that cognition is negatively influenced by higher cortisol exposure to the brain. no studies have been performed to assess the effects of treatment regimens with a low physiological hc substitution dose on cognition in comparison to a high physiological hc substitution dose. these treatment regimens should take body weight and multiple dosing into account. in addition, substitution doses should be monitored by clinical evaluation and biochemical analysis for adverse effects associated with over- or under-replacement. * intervention: patients with secondary adrenal insufficiency will be randomized in two groups to receive either a low dose hc (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose hc (0.4-0.6 mg/kg body weight) or vice versa. at baseline and after both treatment periods, patients will be tested.

Eligibility criteria:
inclusion criteria: * patients with secondary adrenal insufficiency. * age ≥ 18 - 75 years * ≥ one year after tumor treatment with surgery and/or radiotherapy * on stable concomitant medications for at least six months prior to entry of study * body weight 50-100 kg exclusion criteria: * inability of legal consent * documented cognitive impairment * drug abuse/dependence * history of / current psychiatric disorders * use of anti-epileptics (e.g. carbamezapine) * cushing disease * type 1 diabetes or type 2 diabetes with medication known to induce hypoglycemia (f.e. sulfonylurea derivatives * current treatment for second malignancy * have a significant medical condition (e.g. hepatic, respiratory, or cardiovascular) which, in the opinion of the investigator, may interfere with the interpretation of results and safety or efficacy evaluations. * a history of frequent hypocortisolism * hospitalization during study * work in shifts

Keywords: hydrocortisone cognition adrenal insufficiency quality of life common somatic complaints cardiovascular/metabolic profile somatosensation
multimodal approach in ibd patients

Conditions: Ulcerative Colitis; Crohn's Disease; Nonalcoholic Fatty Liver Disease (NAFLD); Vitamin D Deficiency

Summary: the investigators intend to assess the role of several biomarkers in the prediction of relapse in ibd. clinical, laboratory and endoscopic data will be gathered and a predictive score will be derived in order to assess the relapse risk at 1 year.

patients with a confirmed diagnosis of ibd will be prospectively assessed on a yearly basis in order to assess relapse risk factors. disease activity will be assessed using the mayo score for uc patients and cdai for crohn's disease and endoscopic activity will be assessed using the mayo endoscopic subscore for uc patients and the simple endoscopic score for crohn's disease for cd patients. serum and fecal biomarkers will be obtainted at each study visit (c-reactive protein, fecal calprotectin). data about current and past medication for ibd will also be gathered.

Eligibility criteria:
inclusion criteria: * ulcerative colitis or crohn's disease * age over 18 * clinical remission * signed informed consent exclusion criteria: * pregnant women * refusal to sign informed consent

Keywords: ibd ulcerative colitis crohn's disease nafld biomarkers vitamin d
autologous bone marrow concentration for femoral shaft fracture union

Conditions: Bone Marrow; Femoral Shaft Fracture

Summary: this study aims to evaluate the effect of bone marrow concentration on union of femoral shaft fracture by comparing clinical and imaging outcomes between patients receiving intramedullary nail fixation with intraoperative bone marrow concentration and those receiving intramedullary nail fixation only.

femoral shaft fracture is a common orthopaedic injury. intramedullary nail is one of the standard treatments. its primary goal is to develop an osseous bridge between adjacent motion segments to prevent motion, relieve pain, and facilitate bone union. delayed union or nonunion is common in femoral shaft fracture. risk factors include comminuted fracture, open fracture, smoking, diabetes and open reduction of fracture fixation. mesenchymal stem cells are pluripotent cells that can differentiate into multiple mesenchymal tissues, including tenocytes, chondrocytes and osteoblasts, as well as being a source of multiple growth factors to establish an environment conducive to soft and hard tissue regeneration. as bone marrow concentration has high concentration of mesenchymal stem cells, some studies have shown that autologous bone marrow concentration can improve bone healing. therefore, the goal of this study was to evaluate the effect of bone marrow concentration on union of femoral shaft fracture.

Eligibility criteria:
inclusion criteria: * with recent diagnosis of femoral shaft fracture * treated with intramedullary nail fixation * with one or more risk factors of non-union: comminuted fracture, open fracture, smoking, obesity, diabetes, open reduction, * age between 20 and 80 years exclusion criteria: * old femoral shaft fracture * with concurrent major trauma, ex. intracranial hemorrhage, pneumothorax, hemothorax, internal bleeding. * with prior history of femoral surgery * with current or prior history of trauma or infection at femur * with current diagnosis of coagulopathy * with current or prior history of cancer * with current or prior history of hematological disease * pregnancy * patients who will not cooperate with one-year followup

Keywords: bone marrow mesenchymal stromal cells femoral shaft fracture
autologous myoblast intrasphincteric injection for fecal incontinence

Conditions: Fecal Incontinence

Summary: this project aims to offer autologous muscle-derived progenitor cell injection as an efficient mini-invasive surgical therapy that would be simple for the patient and could be used in a majority of cases, including in young women in the post-partum. this approach may provide efficient tissue repair of the striated anal sphincter which is not permitted by existing therapies. this innovative therapy may ultimately be proposed after failure of the common treatments and before an high-risk invasive surgical intervention. besides, injection of muscle-derived progenitor cells in animals has shown very encouraging results of the sphincter function assessed ex vivo. hence, a high benefit may be expected with this approach.

after verification of information and inclusion criteria. patients were randomized to treatment or placebo arms and receive the injections. an evaluation of the function and quality of life are realized. after a period of 6 months, patients in the placebo arm receive the injection of myoblasts that have been preserved.

Eligibility criteria:
inclusion criteria * age between 20 and 65 years * severe fecal incontinence from at least three months * jorge et wexner score ≥ 10 * incontinence refractory to medical treatment and to reeducation from at least three months * incontinence due to lesion of the external anal sphincter * incontinence without significant anal sphincter rupture or rupture ≤ 30% of circumference assessed by endo-anal ultra-sonography * integrity or not of the internal anal sphincter * fecal incontinence with normal rectum capacity (maximum tolerable volume ≥ 150 ml assessed by ano-rectal manometry) * fecal incontinence without associated rectal static disorder on defeco-mri * fecal incontinence without bilateral complete neuropathy assessed by electro-physiology exclusion criteria * fecal incontinence with rupture \> 30 % of the external anal sphincter * fecal incontinence with bilateral lesions on the sacral nerves * crohn's disease or ulcerative colitis * unstable type 1 or type 2 diabetes * myopathy * peripheral or central neurological diseases * treatment with laxatives, suppositories or enema * practice of anal intercourse except if stopped during the study * treatment with immunosuppressive or cytostatic drugs, coa hmg reductase inhibitors, morphine derivatives * treatment of constipation or rectal dyschesia * pregnancy or breast-feeding,lack of effective contraception during the study (female) * allergy to antibiotics (cephalexin, metronidazole)

Keywords: fecal incontinence myoblast surgery
effect of sarcopenia on hepatocellular carcinoma(hcc) after systemic therapies

Conditions: Hepatocellular Carcinoma; Sarcopenia

Summary: sarcopenia is associated with the prognosis of hcc and cholangiocarcinoma. but there has been rare study focusing on the effect of sarcopenia on the prognosis of hcc treated with systemic therapy, such as interventional therapy, targeted therapy, chemotherapy and immunotherapy and so on.

by tracking the short-term and long-term results of hcc patients treated with systemic therapy,the difference of short-term results between patients with sarcopenia and patients without sarcopenia was analyzed, and the correlation between sarcopenia and short-term and long-term results of patients after systemic treatments was explored, so as to improve people's awareness of sarcopenia and pay attention to its prevention and treatment.all implementation details are based on the newest europeanworking group on sarcopenia in older people(ewgsop) definition. the investigators consecutively admitted patients the questionnaire and evaluated the assessment of muscle strength (grip strength test and chair stand test), muscle quantity (l3 plane total skeletal muscle area) and physical performance (gait test) following the f-a-c-s approach, to confirm patients with sarcopenia accurately. and by tracking the short-term and long-term outcomes, the differences were analyzed and the relationship between sarcopenia and prognosis of systemic treatments was explored.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hepatocellular carcinoma * no cancer other than liver cancer has been diagnosed * age ≥18 years * child-pugh score≤7 exclusion criteria: * uncompleted standard tests and questionnaires * received other therapies * patients who had other causes of muscle weakness (injury, fracture, stroke, etc.) * patients who missing ct data or ct scan did not reach the level of the third lumbar vertebra (l3) * lost follow-up

Keywords: hepatocellular carcinoma sarcopenia prognosis adverse events systemic therapy
adding maraviroc to the haart regimen of well controlled hiv-infected patients

Conditions: HIV Infection

Summary: many patients on highly active antiretroviral therapy (haart) are able to achieve a sustained response with viral loads becoming undetectable and staying undetectable, but do not have an increase in their cd4 counts to levels greater than 500. adding maraviroc to the treatment regimen of these patients may result in an increase in their cd4 counts. as the patient would be continuing their prior regimen, they will likely continue with full control of viral replication.

this is a prospective, open-label, non-controlled, non-randomized, single center study of the effect of adding the antiretroviral maraviroc to the antiretroviral treatment regimen (haart)of patients who have achieved a sustained virologic response to haart but have had a sub-adequate immunologic response to treatment. patients who have had a full virologic response (as defined by hiv-1 viral loads of \< 48 copies/ml) for 12 months or more are defined as having a sub-adequate immunologic response if their cd4 lymphocyte count has not gone above 500. this pilot study will contain up to 30 patients who will be followed over a period of 12 months starting from the date of enrollment and addition of maraviroc to their current highly active antiretroviral therapy regimen. the main outcome to be followed is the cd4 lymphocyte counts at baseline and after 12 months of treatment with the addition of maraviroc.

Eligibility criteria:
inclusion criteria: 1. hiv-1 positive. 2. receiving highly active antiretroviral therapy (haart). 3. hiv-1 viral load of \< 48 copies for 12 months or more. 4. cd4 lymphocyte count that has not gone above 500. - exclusion criteria: 1. severe hepatic impairment (cirrhosis) or active hepatitis c with liver transaminases \> 5 times normal. 2. severe renal impairment (creatinine clearance \< 30 ml/min) or end-stage renal disease (esrd) who are taking potent cyp3a4 inhibitors or inducers. 3. receiving certain necessary medications that have the potential for serious drug-drug interactions with maraviroc. -

Keywords: maraviroc haart regimen immunologic response
dexmedetomidine as an adjuvant to bupivacaine in scalp block versus bupivacaine alone for postoperative pain management in patients undergoing craniotomy

Conditions: Dexmedetomidine; Adjuvant; Bupivacaine; Scalp Block; Postoperative Pain; Craniotomy

Summary: this study aims to compare dexmedetomidine as an adjuvant to bupivacaine in scalp block versus bupivacaine alone for postoperative pain management in patients undergoing craniotomy.

scalp block is proposed as a multimodal approach to preventing postoperative pain and hemodynamic responses to previous noxious stimulation during the operation. the use of adjuvants, such as dexmedetomidine, a highly selective alpha-2 adrenergic receptor agonist, has recently been studied for its analgesic effects. dexmedetomidine acts additionally to local anesthetics, prolonging their duration of action.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years. * both sexes. * american society of anesthesiologists (asa) physical status i or ii. * undergoing supratentorial elective planned craniotomies. exclusion criteria: * patients refusal. * history of known allergy to the used local anesthetic or dexmedetomidine. * bleeding disorders. * evidence of local infection at the site of injection. * emergency craniotomy. * psychotic disorder. * patients who will not be extubated in the operating room after surgery.
usage of high flow nasal cannula in preventing desaturations in elderly patients going for lower limb surgeries

Conditions: Hypoxemia During Surgery; Atelectasis

Summary: to study the effect of high flow nasal cannula in comparisons with nasoprong used intraoperatively in patients oxygenation status

to observe the effect of high flow nasal cannula used intraoperatively compared to normal oxygen therapy (nasoprong) at a same fraction of inspired oxygen (fio2) in elderly patients who are going for orthopaedic surgeries under central neuraxial block. oxygenation will be access with intermittent blood gas. atelectasis will be access via chest x-ray , compared to a baseline chest x-ray, validated by a blinded radiologist

Eligibility criteria:
inclusion criteria: 1. american society of anesthesiologists (asa) i, ii or iii patients. 2. patients age 60 years and above 3. patients scheduled for total knee replacement therapy and hip surgeries under central neuraxial block under the elective and emergency list. exclusion criteria: 1. patients with pre-operative spo2\<94% 2. patients delirious or demented / unable to give consent. 3. patients with pre-existing pneumonia (defined as the initiation of antibiotics for suspected infection with one or more of the following: new or changed sputum; new or changed lung opacities; fever; white blood cell count \>12 × 109 litre-1 )15 4. bmi ≥35

Keywords: high flow nasal cannula elderly orthopaedic hypoxaemia regional anaesthesia
alcohol and bariatric surgery

Conditions: Obesity

Summary: the investigators wish to study the effects of alcohol on three forms of bariatric surgery, roux-en-y gastric bypass (rygb), sleeve gastrectomy (sg) and laparoscopic adjustable gastric banding (lagb) and compare them with a non-surgical group. the surgery is not part of the clinical trial. if insurance does not cover the procedure, then the patient is responsible for payment of the surgical process. the investigators are doing pre and post surgery testing to provide a better understanding of the effect of bariatric surgery-induced weight loss on 1) alcohol absorption, distribution and elimination from the body, 2) the effects of alcohol on mood, and 3) the effects of alcohol on driving.

the study includes seven groups of women: one group will be undergoing rygb another group will be undergoing lagb, a third group will be undergoing sg, the fourth group will be women who underwent rygb 1-5 years ago, the fifth group will be women who underwent lagb 1-5 years ago, the sixth group will be women who underwent sg 1-5 years ago and the seventh group will be women who have equivalent age and body mass index than women in the groups who underwent rygb or sg 1-5 years ago but did not have bariatric surgery (non-surgical group).

Eligibility criteria:
inclusion criteria: * female * drink at least 1 standard alcoholic beverage/ month * underwent rygb, sg, or lagb 1-5 years ago or will undergo rygb, sg, or lagb surgery * did not undergo bariatric surgery (for the non-surgical group) exclusion criteria: * male * smoker or quit \< 6 months ago * anemia * liver disease * body weight \> 450 pounds * taking medications that can interact with alcohol metabolism or the subjective effects of alcohol

Keywords: alcohol metabolism bariatric surgery